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Abstract
Pax6 and Pax6(5a) are two isoforms of the evolutionary conserved Pax6 gene often co-expressed in specific stochiometric
relationship in the brain and the eye during development. The Pax6(5a) protein differs from Pax6 by having a 14 amino acid
insert in the paired domain, causing the two proteins to have different DNA binding specificities. Difference in functions
during development is proven by the fact that mutations in the 14 amino acid insertion for Pax6(5a) give a slightly different
eye phenotype than the one described for Pax6. Whereas quite many Pax6 target genes have been published during the
last years, few Pax6(5a) specific target genes have been reported on. However, target genes identified by Pax6 knockout
studies can probably be Pax6(5a) targets as well, since this isoform also will be affected by the knockout. In order to identify
new Pax6 target genes, and to try to distinguish between genes regulated by Pax6 and Pax6(5a), we generated FlpIn-3T3
cell lines stably expressing Pax6 or Pax6(5a). RNA was harvested from these cell lines and used in gene expression
microarrays where we identified a number of genes differentially regulated by Pax6 and Pax6(5a). A majority of these were
associated with the extracellular region. By qPCR we verified that Ncam1, Ngef, Sphk1, Dkk3 and Crtap are Pax6(5a) specific
target genes, while Tgfbi, Vegfa, EphB2, Klk8 and Edn1 were confirmed as Pax6 specific target genes. Nbl1, Ngfb and seven
genes encoding different glycosyl transferases appeared to be regulated by both. Direct binding to the promoters of Crtap,
Ctgf, Edn1, Dkk3, Pdgfb and Ngef was verified by ChIP. Furthermore, a change in morphology of the stably transfected Pax6
and Pax6(5a) cells was observed, and the Pax6 expressing cells were shown to have increased proliferation and migration
capacities.
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Introduction
Pax6 is an evolutionary conserved transcription factor
important for proper embryo development, while it also has
crucial functions in certain tissues in adults. Pax6 is expressed in
the central nervous system, the olfactory epithelium, the eye and
the pancreas [1]. Heterozygous Pax6 mutations cause the eye
phenotype aniridia in humans, and is also associated with
glucose intolerance [2], lack of pineal gland and absence of the
anterior comissure [3], as well as various neural phenotypes
associated with aniridia [4] and references therein). Homozy-
gous Pax6 mutants have no eyes, nasal structures and pancreas
in addition to severe brain defects, and die shortly after birth
[5]. Pax6 has two DNA binding domains: the bipartite paired
domain (PD) and the paired type homeodomain (HD) [6]. Both
can bind DNA independently, but they can also cooperate. The
C-terminal part of Pax6 functions as a transcriptional activation
domain [7,8]. The Pax6DPD isoform contains only the HD and
transcriptional activation domain (TAD). Moreover, a splice
variant of Pax6 which has a 14 amino acid insertion in the N-
terminal part of the PD gives rise to the Pax6(5a) isoform that
has a completely different DNA binding specificity [9]. Isolated
Pax6 DNA binding sites verified by DNA-footprinting are long
(at least 20–30 bp) and seemingly versatile [10–15]. These sites
represent Pax6 binding in vivo and can include contribution from
both the paired domain and the homeodomain. A PCR based
binding site selection method has been used to select the optimal
binding sites for both the ordinary Pax6 paired domain [16] and
the Pax6(5a) paired domain [9] in vitro.I nt h i sc a s et h es e l e c t e d
consensus sequences termed p6CON and 5aCON, were 20 and
22 bp long, respectively. Whereas p6CON is bound by one
paired domain, the 5aCON consensus looks like two tandem
repeats, and are preferably bound by four Pax6(5a) paired
domains simultaneously [9,17]. Importantly, Pax6(5a) is not
able to bind P6CON sites, but Pax6 can bind 5aCON sites
albeit as a monomer, and not as efficiently as Pax6(5a). 5aCON
halfsites can be bound by Pax6(5a) monomers, but not by Pax6
at all [9].
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the eyegone (eyg) and twin-of-eyegone (toe) genes in Drosophila
are thought to be Pax6(5a) homologues with regard to DNA
binding properties since they lack the N-terminal part of the paired
domain [20]. Both Pax6 isoforms are expressed together in various
tissues in the eye and brain, and seem to functionally interact to
stimulate transcription of target genes [21,22]. In reporter gene
assays the optimal ratio between Pax6 and Pax6(5a) was shown to
be 8:1 or 1:1 [23]. In the early developing mouse brain the Pax6
and Pax6(5a) transcripts are expressed in a ratio of 8:1 [17,24] but
from E12.5 to E14.4 this ratio falls to 3:1 [24]. A decrease in the
ratio between Pax6 and Pax6(5a) is also observed during chick
retina development [25]. However in adult human lens and
cornea, as well as in monkey retina, there seem to be equal levels
of PAX6 and PAX6(5a) [26]. Even though they are expressed
together, the two Pax6 isoforms have different functions. This is
illustrated by the fact that mice lacking the Pax6-5a isoform have
specific eye defects and also a difference in anatomy of the
pancreas [27]. A missense mutation within Pax6 exon 5a has been
described in four families with members suffering from Peters
anomaly, congenital cataracts, Axenfeldt anomaly and/or foveal
hypoplasia [28]. In line with this, in chicken retina the expression
of Pax6(5a) is especially high in the fovea [25]. Pax6(5a)
overexpression in transgenic mice causes cataracts and upregula-
tion of alpha5-beta1-integrin [29]. Pax6 and Pax6(5a) are both
reported to be involved in proliferation and differentiation in
several studies, but they seem to play different parts. For example,
in ovo electroporation of chick retina with either Pax6 or Pax6(5a)
showed that both isoforms caused increased retinal cell prolifer-
ation, but Pax6(5a) induced ectopic differentiation of the retina to
a stronger degree than Pax6 [25]. Pax6(5a) was also shown to
strongly induce murine embryonic stem cells to differentiate into
neurons, while Pax6 did not have such a strong effect [30].
However, Haubst and colleagues came to a different conclusion
when they investigated the effects Pax6 mutations in the paired
domain (PD), the PD-5a insertion and the homeodomain had on
brain development [31]. They showed that Pax6 PD mutations
affected both proliferation and differentiation, while the PD-5a
mutation only affected proliferation and had no effect on cell fate/
differentiation in brain development.
In the search for novel Pax6 target genes, gene expression
microarrays have been used for both Pax6 overexpressing [21] and
Pax6 heterozygous mutant mouse lenses [32], mouse Pax6
homozygous mutant forebrain [33,34] and rat Pax6 homozygous
mutant hindbrain [35]. There has also been performed a high-
throughput screening using in-situ hybridization to look for genes
regulated by Pax6 [36].
Not much is known about Pax6(5a) target genes, and the
problem might be in the co-expression with Pax6 making it hard
to distinguish between combined- and isoform-specific effects on
gene expression. In this study we constructed Flp-In 3T3 cell lines
stably expressing either Pax6 or Pax6(5a). 3T3-cells have no
expression of the endogenous Pax6 gene locus and the constructed
cell lines thus express only the stably transfected isoform, either
Pax6 or Pax6(5a). They therefore seem to be ideal to study
individual target genes regulated by either Pax6 or Pax6(5a). We
have performed a gene expression microarray showing that
majority of the regulated genes are associated with the
extracellular region and include growth factors, growth factor
receptors, cell adhesion molecules, extracellular matrix compo-
nents, secreted inhibitors and peptidases. Interestingly, when
target genes were analyzed with regard to gene ontology, the four
groups of Pax6 and Pax6(5a) up- and downregulated genes had
obvious differences in biological properties. A change in
morphology of the Pax6 and Pax6(5a) expressing cells was also
observed, as well as an increase in proliferation and migration.
Results
Constuction of Flp-In 3T3 cell lines expressing either Pax6
or Pax6(5a)
The two Pax6 isoforms, Pax6 and Pax6(5a), are co-expressed in
both the eye and the brain in tissue specific ratios. Searching for
target genes by use of tissues or cell lines from Pax6 mutant
animals, or by knocking down Pax6 with siRNA will not
distinguish between Pax6 and Pax6(5a) target genes since both
Pax6 isoforms will be affected. It could be that several of the
identified Pax6 target genes are common for both isoforms, but
one would expect each isoform to also be able also to regulate
genes on their own since their binding site preferences are
different. In order to identify new Pax6 target genes, and to try to
distinguish between genes regulated by Pax6 and Pax6(5a), we
generated FlpIn-3T3 (Invitrogen) cell lines stably expressing the
mouse Pax6 or Pax6(5a) cDNA. The mouse fibroblast 3T3 cell line
was specifically chosen because it does not express any endogenous
Pax6. Successful flip-in and expression of Pax6 and Pax6(5a) were
shown both by RT-PCR and Western blotting (Fig. 1 A and B).
Figure 1. RT-PCR and Western blot confirm expression of the
correct Pax6 isoform in the FlpIn-3T3 Pax6 and Pax6(5a) cell
lines. (A) RT-PCR primers were designed so that the alternatively
spliced exon 5a (42 bp) would be included in the PCR product if
present. HPRT specific primers were used to show equal input of cDNA.
Neither Pax6 nor Pax6(5a) is present in the FlpIn-3T3 control cell line. (B)
Western blot with a Pax6 specific antibody (Millipore # AB2237)
confirms expression of Pax6 and Pax6(5a) proteins in the respective cell
lines. The lower molecular weight band of equal size for each of the
Pax6 cell lines is the Pax6DPD isoform generated from an internal AUG
startcodon in the link between the paired domain and the homeodo-
main.
doi:10.1371/journal.pone.0031915.g001
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different sets of genes regulated by Pax6 and Pax6(5a)
Eight samples of RNA from the three different cell lines were
sent for microarray analyses on an Illumina Mouse Ref-8 V1.1
chip (Turku Centre for Biotechnology, Finland). The samples
included three different RNA preparations from two different
passages for the FlpIn-3T3 (control) and FlpIn- Pax6(5a) cell lines,
and two different RNA preparations from two different passages
for FlpIn-Pax6 cell lines. We found a small but significant number
of genes to be regulated by the two Pax6 isoforms when comparing
gene expression in the 3T3-Pax6 and 3T3-Pax6(5a) cell lines to
gene expression in the 3T3-FlpIn cell line. A total number of 221
genes were regulated by Pax6 (130 down and 81 up), whereas
Pax6(5a) regulated a smaller number of genes, totally 82 (52 down
and 30 up) with a false discovery rate (FDR/p-value) of ,0.001
(Table 1). A Venn diagram (Fig. 2) shows that only 50 genes are
regulated by both Pax6 and Pax6(5a), whereas Pax6 affects 171
genes and Pax6(5a) regulates 32 genes. The full list of genes
regulated by Pax6 and by Pax6(5a) can be seen in Tables S1 and
S2, respectively. Already known Pax6 target genes such as Ncam1
[37,38], Vegfa [39], Dkk3 [34] and Crabp1 [34] are on the list of
regulated genes. Interestingly, Ncam1 which is published as a Pax6
target gene, is only found on the Pax6(5a) list, where it is
upregulated with a 2.4 fold change.
Gene ontology analysis shows that a majority of the
regulated genes are associated with the membrane and
extracellular matrix
The gene lists with up- or downregulated genes (threshold 1, see
table 1) were analysed by the Database for Annotation,
Visualisation and Integrated Discovery (DAVID) [40,41].
To summarize, 25–30% of the genes regulated by both Pax6
and Pax6(5a) in the 3T3-FlpIn cell line are associated with the
extracellular region when looking at the term cellular compart-
ment (CC). Furthermore, looking at protein information resource
(PIR) keywords, ‘‘glycoprotein’’, ‘‘signal’’ and ‘‘secreted’’ are
associated with 20–50% of the regulated genes in the Pax6 and
Pax6(5a) cell lines (Table 2). All these observations fit with the
molecular function (MF) of regulated genes being associated with
growth factor binding, cytokine binding, carbohydrate binding,
kinase- and receptor activities and enzymatic activities (Table 3).
When one looks at the biological properties (BP) there are
interesting differences between the four groups of genes: those
associated with cell growth and adhesion are upregulated by
Pax6, while genes associated with signalling pathways are
downregulated. Pax6(5a) upregulated genes are associated with
cell adhesion, motion and migration, but are also related to
response to starvation and extracellular stimulus. Pax6(5a)
downregulated genes are mostly associated with metabolic
processes (Table 4).
Functional annotation clustering (which is a function in the
DAVID database that cluster somewhat heterogeneous, yet
highly similar, annotations into functional groups based on the
degree of their co-associations with the genes on the users’
individual gene lists), confirmed the above observations (data not
shown). For both Pax6 and Pax6(5a) downregulated genes, the
cluster giving the highest score contained the term ’’extracellular
matrix’’. For Pax6 upregulated genes it was the cluster with the
term ‘‘cell adhesion’’ that gave the highest score, while for
Pax6(5a) upregulated genes the cluster with the highest score
contained ‘‘disulfide bond’’ and ‘‘signal’’, followed by a cluster
containing the ‘‘cell adhesion’’ term.
A group of glycosyl transferases are downregulated by
Pax6 and Pax6(5a)
An additional gene ontology database (eGOn, http://www.
genetools.microarray.ntnu.no/adb/index.php) was also used for
analysis [42]. With this tool one can compare lists of genes and
look for similarities or differences. We compared the list of
upregulated genes with the list of downregulated genes for both
Pax6 and Pax6(5a), with the purpose to see if there were
significant differences with regard to molecular function or
biological properties in the groups of genes being up- or
downregulated. The result showed that a significant group of
genes being downregulated by Pax6 and Pax6(5a) is glycosyl
transferases, while significantly more genes associated with the
term kinase where found in the upregulated gene lists. This would
imply that changed expression of Pax6 and/or Pax6(5a) could
cause post-translational differences in both the glycosylation
pattern and phosphorylation status of proteins. This will probably
have impact on cell adhesion, motility and signalling pathways.
RT-PCR verified that all the tested glycosyl transferases (St6gal1,
St3gal6, Fut8, Mgat3, Gcnt1, Gcnt2 and Ugt1a7c)w e r ed o w n r e g u -
lated in the Pax6 and Pax6(5a) expressing FlpIn-3T3 cells (Fig. 3).
qPCR confirmed the RT-PCR results, but the fold magnitude of
downregulation varied between experiments. Therefore the result
of four independent qPCRs are shown in the figure 3. For most of
the glycosyl transferases transcripts, a modest (two-fold) down-
Figure 2. Venn diagram shows the number of individual and
common sets of genes regulated by Pax6 and Pax6(5a) in a
gene expression microarray. Three RNA samples from the FlpIn-3T3
control cell line, three samples from the FlpIn-3T3 Pax6(5a) cell line and
two samples from the FlpIn-3T3 Pax6 cell line were sent for microarray
analysis on the Illumina Mouse Ref-8 V1.1 chip. The number of genes
differentially regulated as scored by threshold 1 is shown, while use of
threshold 2 gave numbers shown in parentheses. (Threshold 1 is FDR p-
value 0.001, FC 1.7, log FC 0.77. Threshold 2 is FDR p-value 0.01, FC 1.5,
log FC 0.58).
doi:10.1371/journal.pone.0031915.g002
Table 1. Number of genes differentially regulated in the 3T3-
Pax6 and 3T3-Pax6(5a) cell lines compared to the 3T3-control
cell line.
Pax6(5a)/
control
#
Pax6/
control
#
Pax6(5a)/
control
&
Pax6/
control
&
Up 30 81 108 207
Down 52 130 130 289
Total 82 221 238 496
#Threshold 1 (FDR p-value 0.001, FC 1.7, log FC 0.77),
&Threshold 2 (FDR p-value 0.01, FC 1.5, log FC 0.58), Illumina Mouse Ref-8 V1.1
chip.
doi:10.1371/journal.pone.0031915.t001
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St3gal6 showed strong downregulation by Pax6 and Pax6(5a)
respectively. The high deviation in fold downregulation could be
caused by the sensitivity of the qPCR method which enable us to
detect very small amounts of transcripts (giving high Ct values,
with high deviation). Alternatively, other factors than Pax6(5a)
may also influence the expression of St3gal6 contributing to the
observed variation in expression levels.
Pax6 and Pax6(5a)specific target genes are verified by
qPCR
Quantitative real time PCR primers were designed for some of
the genes associated with extracellular matrix (Tgfbi, Vegfa, Adamts-
2 and Crtap) and cell adhesion (Ctgf, Cdh5 and Ncam). Some genes
representing the KEGG pathway ‘‘Pathways in cancer’’ (Pdgfra,
Pdgfrb, Vegfa, PPP3ca, EphB2 and Prkcn) and the gene ontology term
‘‘regulation of transmission of nerve impulses’’ (Bdnf, Ngfb, Klk8 and
Edn1) were also included (Fig. 4). As well, we performed qPCR on
some genes listed as Pax6(5a) specific target genes (Ncam1, Pdgfb,
Ngef, Dkk3, Hist1h1c, Sphk1and Nbl1). When a cut-off of fold change
(FC) 1.7 was used, most of the genes showed up- or downregu-
lation as expected from the microarray result. However, Adamts2,
Pdgfra, Ppp3ca and Bdnf did not seem to be regulated at all, and
Prkcn value was borderline. According to microarray results Tgfbi,
Vegfa, EphB2, Klk8 were expected to be regulated by Pax6 only,
and this was confirmed by qPCR. Likewise, Crtap was downreg-
ulated and Ctgf was upregulated as expected by both Pax6 and
Pax6(5a). We noticed that Crtap is much stronger downregulated
by Pax6(5a) (74 fold) than by Pax6 (4 fold). Further, for several of
the Pax6 specific target genes tested, real time PCR showed
regulation by the Pax6(5a) isoform as well (e.g Edn1, Ngfb, Cdh5),
even though the Edn1 gene in particular seemed to be much
stronger regulated by Pax6 than Pax6(5a) (17 fold compared to 3.7
fold) (Fig. 4).
Table 3. Percentage of Pax6/Pax6(5a) up- or downregulated genes associated with various Molecular Function (MF) gene
ontology terms.
GO-term: MF
# Pax6 up GO-term: MF
#
Pax6
down
GO-term:
MF
#
Pax6(5a)
up GO-term: MF
#
Pax6(5a)
down
Insulin like growth
factor binding
4,20% Growth factor binding 5,60% Growth factor
activity
10,70% Cytokine receptor
activity
6,20%
Growth factor binding 4,20% Polysaccharid binding 5,60% Carbohydrate
binding
10,70% Cytokine binding 6,20%
Enzyme inhibitor activity 5,60% Pattern binding 5,60% Glucoronosyltransferase
activity
4,20%
Serine type endopeptidase
activity
4,20% Cytokine binding 4,80% Cytoskeletal protein
binding
8,30%
Cytoskeletal protein binding 6,90% Transmembrane receptor
protein tyr kinase activity
4,00% Endopeptidase
activity
8,30%
Endopeptidase activity 6,90% Vegf receptor activity 2,40%
Glucosaminoglycan binding 4,80%
Heparin binding 4,00%
#According to the Database for Annotation, Visualisation and Integrated Discovery (DAVID). Most significant (lowest p-value) at top.
doi:10.1371/journal.pone.0031915.t003
Table 2. Percentage of Pax6/Pax6(5a) up- or downregulated genes associated with Gene ontology (GO) terms ‘‘Cellular
compartment’’ and ‘‘SP_PIR_keywords’’.
GO-term
# Pax6 up Pax6 down Pax6(5a) up Pax6(5a) down
Cellular compartment:
Extracellular region 25,00% 26,20% 32,10% 29,20%
Extracellular matrix 6,90% 10,30% - 12,50%
Ancored to membrane - - 14,30% -
Plasma membrane - 31,70% - -
SP_PIR_KEWORDS
$:
Secreted 22,00% 23,00% 32,10% 25,00%
Signal 30,60% 38,10% 46,40% 37,50%
Cell adhesion 9,70% - 17,90% -
Disulfid bond 25,00% 34,90% 42,90% 39,60%
Glycoprotein 27,80% 50,80% 39,30% 47,90%
#According to the Database for Annotation, Visualisation and Integrated Discovery (DAVID). Most significant (lowest p-value) at top.
$SP_PIR=Swiss Protein_ Protein Information Resource.
doi:10.1371/journal.pone.0031915.t002
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as Pax6(5a) specific targets
Generation of the Pax6(5a) expressing FlpIN-3T3 cell line
provided an unique opportunity to search for genes specifically
regulated by Pax6(5a). As the Venn diagram in figure 2 implies, 82
genes are indicated as targets for Pax6(5a), with 50 of these also
being regulated by Pax6, leaving 32 as exclusive Pax6(5a) targets
(Table 5). Quantitative real time PCR was performed with primers
designed for some of the exclusive Pax6(5a) target genes listed in
table 5: Ncam1, Pdgfb, Ngef, Dkk3 and Hist1h1c (upregulated) and
Sphk1and Nbl1 (downregulated). The overall result confirmed the
gene expression microarray data, though there were differences in
the fold regulation compared to the microarray. However, most of
the genes seemed to be regulated by Pax6 in addition to Pax6(5a),
even though Pax6(5a) regulation was more prominent (Fig. 5).
Ncam1 has already been identified as a Pax6 target gene [37,38].
Interestingly, the FlpIn 3T3-Pax6 cell line does not have
significant increase in transcription of Ncam1 compared to control
cells, while the qPCR results from the Pax6(5a) cell line show that
it is upregulated 11 fold (Fig. 5). Expression of Ngef is about 12 fold
upregulated in the Pax6(5a) cell line. Dkk3 is 24 fold upregulated in
the Pax6(5a) cell line, and almost 6 fold upregulated in the Pax6
expressing cell line. Sphk1 was differentially regulated only in the
Pax6(5a) cell line (about 3 fold down), while Nbl1, which was also
supposed to be a Pax6(5a) specific target gene, was almost equally
downregulated by Pax6 and Pax6(5a) (24.7 and 26.0 fold,
respectively, Fig. 5) in the qPCR assay. Of notice, Pdgfb which was
identified by the microarray as an exclusive Pax6(5a) target gene,
showed only a slight upregulation by Pax6(5a) in qPCR (1.6 fold).
However, Pdgfb turned out to be 27.8 fold downregulated in the
3T3-Pax6 cell line. It is an interesting deviation from the
microarray results which we have no explanation for.
Figure 3. RT-PCR and real time qPCR with primers specific for seven glycosyl transferases confirms that this group of genes is
downregulated by both Pax6 and Pax6(5a). Primers were designed against Ugt1a7, Fut8, Gcnt2, St3gal6, St6gal1, Gcnt1 and Mgat3. All showed
downregulation of transcription of these genes in both the Pax6 and the Pax6(5a) cell lines compared to the FlpIn-3T3 control cell line. Pictures are
representative of three experiments. The fold change value (FC) from the gene expression microarray is included in the table to the right. The Fut8 FC
values for Pax6 and Pax6(5a), and the Gcnt2 value for Pax6(5a) have a p-value=0,01(threshold 2), while the rest of the FC values listed have a p-value
of 0.001 (threshold1). Four independent real-time qPCR experiments are included (Exp.1-Exp.4), and the results are presented as FC in cDNA
concentrations in the FlpIn-3T3 Pax6 and Pax6(5a) cell lines compared to the FlpIn-3T3 control cell line, after normalization against two housekeeping
genes (Nono and Tfrc).
doi:10.1371/journal.pone.0031915.g003
Table 4. Percentage of Pax6/Pax6(5a) up- or downregulated genes associated with various Biological Property (BP) gene ontology
terms.
GO-term: BP
# Pax6 up GO-term: BP
#
Pax6
down GO-term: BP
#
Pax6(5a)
up GO-term: BP
#
Pax6(5a)
down
Regulation of cell growth 5,60% Vegf signaling pathway 4,80% Cell adhesion 17,90% Uronic acid
metabolic process
4,20%
Cell adhesion 11,10% Enzyme linked receptor
protein sign pathway
9,50% Cell motion 14,30% Glucoronate
metabolic process
4,20%
Regulation of transmission
of nerve impulses
5,60% Transmembrane receptor
prot tyr kinase sign pathway
7,90% Cellular response
to starvation
7,10% Aminoglycan
metabolic process
6,20%
Cell-cell adhesion 6,90% Lung development 4,80% Cell-cell adhesion 10,70% Sulfur metabolic
process
6,20%
#According to the Database for Annotation, Visualisation and Integrated Discovery (DAVID). The four most significant terms for each dataset are included, with the most
significant (lowest p-value) at top.
doi:10.1371/journal.pone.0031915.t004
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binding sites in selected target genes
Both Pax6 and Pax6(5a) have very divergent consensus binding
sites around 20 nucleotides long. For Pax6, the consensus site selected
by in vitro binding of recombinant Pax6 to random oligonucletotides,
SELEX [16] and the consensus site selected based on known Pax
binding sites[6] wereboth used tosearch forPax6binding sitesinthe
promoter regions of some of the selected target genes. There are not
many published Pax(5a) target genes, so not a lot of in vivo binding
sites have been identified. However, one study describing in vitro
selection of binding sites for this isoform has been published [9]. The
three different consensus sites p6CON [16], Pax6 consensus [6] and
5aCONhalf-site[9]wereusedtosearchforpatternsinthepromoters
of mouse Dkk3,Ncam1,Ngef,Sphk1,Ctgf,Edn1,Crtap,Vegfaand Pdgfb by
the use of GCG Findpatterns, allowing 2 mismatches. Two thousand
bp upstream and 500 bp downstream of the first exon were used as
input for each gene. The two used Pax6binding sites gave several hits
for each promoter only when a mismatch of 2 nucleotides was
Figure 4. Real time quantitative PCR verifies differentially regulated genes in both the FlpIn-3T3 Pax6 and Pax6(5a) cell lines.
Primers were designed for genes representative for the gene ontology terms ‘‘Extracellular matrix’’ (Adamts2, Tgfbi, Vegfa and Crtap), ‘‘Cell adhesion’’
(Ctgf, Cdh5, Ncam1 and Ngef), ‘‘Pathways in cancer’’ (Ephb2, Pdgfra, Pdgfrb, Ppp3ca, Prkcn and Vegfa) and ‘‘Regulation of transmission of nerve
impulses’’ (Bdnf, Edn1, Klk8 and Ngfb) and used in qPCR. Results are means of three independent experiments and are presented as fold change in
cDNA concentrations in the FlpIn-3T3 Pax6 and Pax6(5a) cell lines compared to the FlpIn-3T3 control cell line, after normalization against two
housekeeping genes. The fold change values obtained for the same genes in the Illumina gene expression microarray are given in the table to the left
of each graph for comparison.
doi:10.1371/journal.pone.0031915.g004
Table 5. Unique Pax6(5a) regulated genes.
Entrez_ID Symbol Gene name FC
229672 Gm566 NA 7,859115
50781 Dkk3 dickkopf homolog 3 (Xenopus laevis) 5,279555
53972 Ngef neuronal guanine nucleotide exchange factor 3,776922
50708 Hist1h1c histone cluster 1, H1c 3,248262
68024 Hist1h2bc histone cluster 1, H2bc 2,74685
17069 Ly6e lymphocyte antigen 6 complex, locus E 2,735913
57875 Angptl4 angiopoietin-like 4 2,485674
17967 Ncam1 neural cell adhesion molecule 1 2,44828
192897 Itgb4 NA 2,296179
213948 Atg9b ATG9 autophagy related 9 homolog B (S. cerevisiae) 2,178804
18591 Pdgfb platelet derived growth factor, B polypeptide 2,002118
76071 Jakmip1 janus kinase and microtubule interacting protein 1 1,945522
21873 Tjp2 tight junction protein 2 1,883161
69550 Bst2 bone marrow stromal cell antigen 2 1,799411
225608 Sh3tc2 SH3 domain and tetratricopeptide repeats 2 1,787549
69032 Lyzl4 lysozyme-like 4 1,739619
620078 LOC620078 RIKEN cDNA C130026I21 gene 1,73713
17064 Cd93 CD93 antigen 1,726663
110074 Dut deoxyuridine triphosphatase 21,80608
17965 Nbl1 neuroblastoma, suppression of tumorigenicity 1 21,81722
15893 Ica1 islet cell autoantigen 1 21,90903
100689 Spon2 spondin 2, extracellular matrix protein 21,96962
17022 Lum lumican 21,99828
21961 Tns1 NA 22,00857
223332 Ranbp3l RAN binding protein 3-like 22,09339
12061 Bdkrb1 bradykinin receptor, beta 1 22,1142
16164 Il13ra1 interleukin 13 receptor, alpha 1 22,11692
331532 Tceal5 transcription elongation factor A (SII)-like 5 22,14302
13179 Dcn decorin 22,32046
216725 Adamts2 a disintegrin-like and metallopeptidase (reprolysin type) with
thrombospondin type 1 motif, 2
22,52677
20698 Sphk1 sphingosine kinase 1 22,93929
319909 5430433G21Rik RIKEN cDNA 5430433G21 gene 23,08482
doi:10.1371/journal.pone.0031915.t005
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quite degenerate to start with, the value of the obtained sites with two
allowed mismatches is not clear. More attention was paid to the
possible Pax6(5a) binding sites, since less is known about Pax6(5a)
target genes in the literature. Results for the 5aCON half-sites are
summarized in Table S3. For Dkk3 several possible Pax6 sites
(p6CON)are located inthe promoterregion,whileonly one Pax6(5a)
(5aCON)half-site is located 200 bp downstream of the TSS in exon1.
This site is conserved in the human DKK3 gene as well (data not
shown). Ncam1 and Ngef, which also are more strongly regulated by
Pax6(5a) than by Pax6, have several 5aCON half-sites located in their
promoter regions. Ncam1 and Ngef have transcripts starting from
two different regions according to the Ensembl genome database, but
the promoter regions of transcripts for both genes (as defined above)
have several 5aCON half-sites. For Ngef it is of interestto note that all
four 5aCON half-sites are located downstream of the TSS for
transcript 202, with three of them clustered around position
2300 bp.ForNcamthe 5aCONhalf-sitesarelocatedbothupstream
and downstream of the TSS. The Ctgf promoter has five 5aCON
half-sites, all upstream of the TSS. No consensus 5aCON half-sites
were found for the Sphk1, Vegfa, Pdgfb and Crtap promoters.
If Pax6 regulation of the target genes is important one would
expect evolutionary conservation of Pax6 binding sites in their
regulatory regions. We used an area of 5000 bp upstream and
1000 bp downstream of the TSS of selected target genes to check
for conserved sites between mice and humans in rVista. Chicken
and zebrafish were also included if the corresponding promoter
areas of the geneswereidentified. Theanalysesweredone forDkk3,
Ctgf, Crtap, Pdgfb, Edn1 and St3gal6. We intended to include
Ncam1, Gcnt1 and Gapdh as well, but here the mouse and human
promoterswerenot very muchconservedto startwith,sowedidnot
continue. The other mouse-human promoter pairs were compara-
blewithatleastsomedegreeofconservation,particularlyinthearea
of the TSS. rVista uses transcription factor binding sites from the
Transfac database. Identified Pax6 binding sites conserved between
mouse and human promoters are shown in table 6. For the 6000 bp
area covering the TSS there were multiple predicted Pax6 binding
sites conserved between mouse and human: Ctgf (39), Edn1 (21),
Pdgfb (18), Crtap (8), St3gal6 (8) and Dkk3 (2). Among the 39 Pax6
binding sites conserved between mouse and human for the Ctgf
gene, one was also conserved in chicken, one in zebrafish, and one
site was conserved in all four species. Among the 8 Pax6 binding
sites conserved between human and mouse for the Crtap gene, 4
were also conserved in chicken. Thus there seem to exist
evolutionary conserved Pax6 binding sites in the regulatory regions
of several of the identified target genes indicating that their
expression indeed can be directly regulated by Pax6.
ChIP-PCR verifies binding of Pax6 and Pax6(5a) to the
promoters of Crtap, Ctgf, Edn1, Pdgfb, Dkk3 and Ngef
Based on the bioinformatic analyses PCR primers were designed
for use in ChIP experiments.Primer sets covered Pax6and Pax6(5a)
putative binding sites, and were used for PCR with ChIPed DNA
from both 3T3-Pax6 and 3T3-Pax6(5a) cell lines. Some of the
primer sets showed enrichment (binding) in both cell lines,
indicating that both Pax6 and Pax6(5a) were associated with the
promoters. This was observed for Crtap, Ctgf, Edn1, and Pdgfb
(Fig. 6A). As expected, the Ngef promoter fragment containing the
putative Pax6(5a) binding site was only enriched in immunopre-
cipitated chromatin from the 3T3-Pax6(5a) cell line (Fig. 6C),
supporting our gene expression- and qPCR-results indicating that
this is a true Pax6(5a) targetgene. Importantly,no amplification was
detected with either the Pax6 or Pax6(5a) ChIP extracts with
primers directed against the promoter region of the housekeeping
gene Gapdh which is not expected to bind Pax6 (Fig. 6A). Presence
of faint bands in the IgG sample for some of the primer sets in
figure 6 indicates unspecific binding of chromatin to either IgG or
the protein A agarose beads. Since the PCR products of the Pax6
ChIPed samples are much more abundant (observed repeatedly) we
feel confident that this area of the promoter is enriched in the Pax6
ChIPed samples. It should be noted that PCRs with two primer sets
for Ncam1, one for Vegfa, and a second primer set for Ngef did not
give any amplification in ChIPed extracts, indicating that the
primers did not cover the Pax6 binding regions of these promoters
(data not shown).To conclude, binding of Pax6 and/or Pax6(5a) to
the promoters of several of the genes differentially expressed
according to the gene expression microarray indicates that these are
direct target genes of Pax6 and Pax6(5a).
Figure 5. Real time quantitative PCR shows that Dkk3, Ncam1, Ngef and Sphk1 are strongly regulated by Pax6(5a). Primers were
designed for some of the genes showing differential expression only in the FlpIn-3T3 Pax6(5a) cell line (Dkk3, Hist1h1c, Nbl1, Ncam1, Ngef, Pdgfb,
Sphk1). Real time quantitative PCR was performed as described in Fig. 4. The fold change values obtained for the same genes in the Illumina gene
expression microarray are given in the table to the left of the graph for comparison.
doi:10.1371/journal.pone.0031915.g005
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is changed along with the proliferation rate and
migration capacity compared to the original FlpIn 3T3
cell line
Consistent with the fact that about half of the target genes
identified by the gene expression microarray are associated with
the membrane and extracellular region, there is a change in
morphology from the FlpIn-3T3 parent cell line to the Pax6 and
Pax6(5a) cell lines. The Pax6 and Pax6(5a) cells are bigger and
more flattened, and seemingly have more protrusions (Fig. 7). In
order to evaluate if Pax6 or Pax6(5a) can influence major
biological processes in 3T3 cells, we employed a recently
introduced xCELLigence platform (Roche) which facilitates
studying of cell proliferation and migration in real time. This is
a microelectric assay based on changing impedance of electrodes
in presence of cells. We recognize that differences in morphology
of the three types of 3T3 cells studied (control, Pax6 and Pax6(5a))
could make impedance-derived absolute values misleading.
Therefore the data are presented as curve slopes or doubling
times. Attachment and initial spreading of the cells typically took
Table 6. Evolutionary conserved Pax6 binding sites identified in the promoter region of several target genes using rVista.
Gene Species Transcript (Ensembl)
Region 25000/+1000 in the promoter
region relative to the TSS (Ensembl)
# of evolutionary
conserved Pax6 bs (rVista)
Dkk3 mouse 201 Chr7: 119301572–119307571 2
human 202 Chr11: 12029178–12035177
Crtap mouse 001 Chr9: 114298794–114304793 8
human 001 Chr3: 33150471–33156470
Ctgf mouse 001 Chr10: 24310248–24316247 39
human 001 Chr6: 132271514–132277513
Edn1 mouse 201 Chr13: 42391639–42397638 21
human 001 Chr6: 12285596–12291595
Pdgfb mouse 201 Chr15:79844239–79850238 18
human 001 Chr22: 39639757–39645756
St3gal6 mouse 001 Chr16: 58522540–58528539 8
human 001 Chr3: 98446099–98452098
Crtap chicken - Chr2: 44496250–44502249 4
#
Ctgf chicken - Chr3: 59158394–59164393 2
$
Ctgf zebrafish 001 Chr20: 25365421–25371420 2*
#Four of the eight sites evolutionary conserved between mouse and human are also conserved in chicken Crtap.
$Two of the 39 sites conserved between mouse and human Ctgf gene are also conserved in chicken, one of these two sites is in addition conserved in zebrafish.
*Two of the 39 sites conserved between mouse and human Ctgf gene are also conserved in zebrafish, one of these two sites is in addition conserved in chicken.
doi:10.1371/journal.pone.0031915.t006
Figure 6. Chromatin immunoprecipitation verifies binding of Pax6 and Pax6(5a) to the promoter region of several target genes.
Chromatin immunoprecipitation with an antibody against Pax6 was done for both the 3T3-Pax6 and the 3T3-Pax6(5a) cell line. IgG was used as a
control. PCR primers were designed so that they should amplify target sequences with putative Pax6 and/or Pax6(5a) binding sites in the promoter
regions of Crtap, Ctgf, Edn1, Pdgf, Dkk3 and Ngef. The number in parenthesis specifies the identity of the primerset used for the observed
amplification. Genomic DNA sampled before adding the antibody (input) was used as a positive control for the PCR reaction, while water was used as
a negative control. The promoter region of Gapdh was included as a region not expected to bind Pax6 or Pax6(5a).
doi:10.1371/journal.pone.0031915.g006
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attachment slopes as depicted on figure 8A. We observed
repeatedly that 3T3-Pax6 cells attach more rapidly than 3T3-
control cells, while no or little difference was seen for 3T3-Pax6(5a)
cells compared to the control. In all experiments (n=4) the 3T3
cell lines expressing either of isoforms of Pax6 had higher
proliferation rates compared to the control cells, with 3T3-Pax6
being most prominent. This is shown both by proliferation slope
analysis (Fig. 8B) and doubling time calculation (Fig. 8C). Finally,
we studied whether serum starved 3T3-Pax6 or 3T3-Pax(5a) cells
had altered migration capabilities in presence of a serum attractant
compared to the 3T3-control cells. 3T3-control cells were unable
to migrate through the uncoated xCELLigence CIM-plate
membrane in any of the three performed experiments. To
minimize the possibility that the observed difference in migration
could be due to faster proliferating Pax6 cells the experiment was
limited to 24 hrs. Furtermore, cells attached to the membrane at
the end of the experiment were stained, and confirmed several fold
differences in cell numbers (data not shown), ruling out the
possibility that the observed changes in impedance were solely
caused by adherence differences. Interestingly, Pax6 expressing
cells did actively pass through the membrane pores following the
serum gradient, while Pax6(5a) seemed to have very limited
influence on the migration abilities of the 3T3 cells (Fig. 8D).
Discussion
In this study FlpIn-3T3 cell lines expressing either Pax6 or
Pax6(5a) were generated and used to search for target genes. Gene
ontology analysis of the resulting gene expression microarray
indicated that a substantial amount of both up- and downregu-
lated genes was associated with the extracellular region and cell
membrane. Regulated genes were also associated with keywords
such as ‘‘glycoprotein’’, ‘‘secreted’’ and ‘‘signal’’. There are
differences in the group of genes regulated by Pax6 and Pax6(5a),
with Pax6 upregulated genes being associated with cell growth and
adhesion, and Pax6(5a) upregulated genes being associated with
cell motion and migration, as well as response to extracellular
signaling and starvation. Downregulated genes were associated
with receptor protein signaling pathways for Pax6 and several
metabolic processes for Pax6(5a). Selected genes were verified as
targets for Pax6 and/or Pax6(5a) by use of qPCR and ChIP. The
possible biological meaning of these results will be discussed below.
Most interestingly, several Pax6(5a) specific target genes were
identified.
Relevance of the cell line used
There is no endogenous Pax6 expression in the murine 3T3
fibroblast cell line. The FlpIn-3T3 cells were therefore chosen to
create a Pax6 and a Pax6(5a) cell line to avoid background
expression when performing the gene expression microarray. We
are aware that certain co-factors that co-regulate transcription by
Pax6 might be missing in the 3T3 cell line, and that this most
probably influenced the resulting number of differentially
regulated genes. In addition, since Pax6 and Pax6(5a) also are
normally co-expressed, they probably influence the transcriptional
activation/repression activity and promoter specificity of each
other. However, these disadvantages can be overcome in future by
transfecting these cell lines with the appropriate co-factors, or the
missing Pax6 isoform, to look at the effect this will have on target
gene expression. The already known Pax6 target genes such as
Ncam1 [37,38], Vegfa [39], Dkk3 [34] and Crabp1 [34] are also
present on the list of regulated genes in our experiment. This
supports the validity of these cell lines for target genes search, and
strengthens our finding of novel Pax6 and Pax6(5a) target genes.
It has been reported that Pax6 and Pax6(5a) positively
autoregulate expression from the endogenous Pax6 promoter in
Neuro2D and NIH3T3 cell lines [43], but we did not observe this
throughout the lengthy study in the FlpIn-3T3 cell lines. The
FlpIn-3T3 Pax6 cell line never expressed Pax6(5a), and the FlpIn-
3T3 Pax6(5a) cell line did not turn on the endogenous Pax6 gene.
A possible explanation for this could be that the chromatin
packing in the FlpIn-3T3 cells is such that the Pax6 autoregulatory
binding sites are not available, or some co-factors are not present
The discrepancy between our results and the result of Pinson et al
Figure 7. The FlpIn-3T3 Pax6 and FlpIn-3T3 Pax6(5a) cell lines have changed morphology compared to the original FlpIn 3T3 cell
line they were generated from. This was repeatedly observed over several passages. Pax6 and Pax6(5a) expressing cells appeared more flattened
and seemed to have more protrusions. The cells on the picture have passage numbers 17, 15 and 11 for the FlpIn-3T3, FlpIn-3T3 Pax6 and FlpIn-3T3
Pax6(5a) respectively. For the pictures on the upper row a 206 magnification is used, for the lower row a 106magnification is used on a Zeizz
Axiovert S100 Microscope with a Nikon Digital Sight DS-5 M camera.
doi:10.1371/journal.pone.0031915.g007
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packing in NIH3T3 and FlpIn-3T3 cells. The transfection
methods or the insertion sites of the FlpIn cassette could have
also contributed to the observed differences.
Expression of neuron-specific genes upon transduction with
Pax6 has previously been shown in HeLa cells [44]. Similar to our
observations in the 3T3 fibroblasts, Cartier and co-workers
showed that HeLa cells change morphology and start to migrate
upon stable transfection with Pax6 [44]. However, although we
also observed expression of some genes with known functions in
neurons (Ngef, Ngfb,Edn1 EphB2, EphB4, Klk8), we did not observe a
post-mitotic phenotype. On the contrary, Pax6 cells seemed to
increase their proliferation rate compared to the control 3T3-
FlpIn cells. Interestingly, whereas Pax6(5a) also seemed to have a
positive effect on the proliferation of the FlpIn-3T3 cells, it
appearently did not increase migration, indicating a functional
difference in the genes regulated by Pax6 and Pax6(5a). However,
there are no reports on Pax6(5a) being expressed alone in vivo;i ti s
always reported to be present in combination with Pax6 in
different ratios. Since Pax6 and Pax6(5a) obviously have different
sets of target genes, one might expect that a change in the
Pax6:Pax6(5a) ratio would cause a change in the gene expression
pattern, ultimately changing the cell properties.
Possible function of Pax6 regulation of target genes
expressed in the extracellular region
In this study we have shown that stable expression of Pax6 or
Pax6(5a) in a fibroblast cell line causes changes in expression of
genes associated with the extracellular region and the membrane.
These genes include receptors, adhesion molecules, secreted
growth factors, secreted inhibitory molecules and matrix modify-
ing enzymes. In addition, several glycosyl transferases are
downregulated, so the glycosylation pattern on the molecules
expressed on the outside of the cells is also expected to be different
compared to fibroblasts not expressing Pax6. Some of the target
genes identified by this approach are already reported to be Pax6
target genes identified in brain, such as Ncam1, Vegfa, Dkk3,
S100A11 and Crabp1 [34,38,39]. Further, the seemingly high
proportion of Pax6 regulated genes in the extracellular region in
this fibroblast cell line (secreted or associated with the membrane),
is supported by several lines of evidence in the literature from
more biologically relevant cells and tissues. Particularly in the
brain, Pax6-positive cells are reported to express specific cell
surface molecules or secret specific extracellular matrix compo-
nents or modifying enzymes. For example, later born cortical
precursor cells in homozygous Pax6 mutant mouse fail to leave the
subventricular zone (SVZ). When transplanted into wild-type
Figure 8. Pax6 expressing FlpIn-3T3 cells have higher prolif-
eration and higher migration capacity compared to FlpIn-3T3
control cells and Pax6(5a) expressing cells. Control, Pax6 and
Pax6(5a) cells were seeded in xCELLigence (Roche) proliferation plates,
cells were left on the bench for 1 hr before the plates were put in the
xCELLigence machine for measurements for 24 hrs. The measured
values were used to calculate the (A) adhesion slope, (B) proliferation
slope and (C) doubling time. For adhesion and proliferation slope
analyses the mean and standard deviation of three independent
experiments are shown. The doubling time analysis shows one
representative experiment out of three, because absolute values were
changing from experiment to experiment probably due to fluctuations
in cell condition. However, described pattern of increased proliferation
(Pax6.Pax6(5a).control) was consistent in all experiments. Each
experiment was done in triplicates (A–C). xCELLigence migration plates
were used to measure the migration, and to calculate the migration
slope (D). One representative experiment out of 3 is shown.
doi:10.1371/journal.pone.0031915.g008
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inability to exit from the SVZ is non-autonomous, and that Pax6 is
needed to generate a cortical environment that permits the later
born precursors to migrate and differentiate [45]. Similarly, Pax6 is
expressed in the anti-hem region shown to be a signaling centre in
the brain. In Pax6 knockout mice cells normally found on the
ventral side migrate to the dorsal side, indicating that Pax6
expressing cells in the antihem function as a barrier, separating the
dorsal and ventral telencephalon [46]. Neural crest derived stem
cells (NCDD) play a crucial role in the development of the front-
nasal tissue. These cells migrate from the midbrain, but in Pax6
homozygous mutant embryos they cannot invade the front nasal
mass [47], due to non cell-autonomous defects in migration. The
HNK-1 epitope is known to inhibit NCDD migration, and this
epitope is ectopically expressed in the Pax6 mutant rat facial
ectoderm [48]. It could be that Pax6 expression normally is needed
to repress the expression of HNK-1 epitope to allow passage of
NCDDs on their way to the front-nasal area. Pax6 is also shown to
regulate migration of neuronal precursors in the cerebral cortex,
and the authors suggested that the primary role of Pax6 during
cortex development was to regulate cell surface properties
responsible for radial migration and cellular identity [49].
Pax6(5a) target genes
For this study it was absolutely necessary to have a separate cell
line for each Pax6 isoform, to be able to distinguish target genes
that are specific to, or common for Pax6 and Pax6(5a). We
identified 32 exclusive Pax6(5a) target genes in the 3T3-Pax6(5a)
cell line. Of the ones tested in qPCR, Dkk3, Ngef and Ncam1
showed the highest fold upregulation by Pax6(5a) (approximately
24, 12 and 11 fold, respectively). However, qPCR showed that
Dkk3 and Ngef were also regulated by Pax6, but to a much lesser
extent – about 2 fold for Ngef and 6 fold for Dkk3. When analyzing
the promoters of these genes (2000 bp upstream and 500–600 bp
downstream of the transcriptional start site) in GCG Findpatterns,
several putative Pax6 and Pax6(5a) binding sites were found when
up to two mismatches compared to the P6CON and 5aCON sites
were allowed [9,16]. Interestingly, Dkk3 was the only gene
containing a sequence similar to the tandemly arranged Pax6(5a)
consensus site (5aCON, [9]), indicating that binding of four
Pax6(5a) paired domains could be possible also on an in vivo
regulated target gene.
Dkk3 is a member of the Dickkopf (Dkk) family of secreted
glycoproteins which is a major class of Wnt signaling regulators,
typically antagonizing Wnt/b-catenin signaling (reviewed in [50]).
While Dkk1, Dkk2 and Dkk4 inhibit Wnt signaling by binding to
LRP5/6 preventing Wnt and Frizzled from forming an active
complex with these receptors, the function of Dkk3 is less clear
[50,51]. In support of our finding of Dkk3 being upregulated by
Pax6(5a) and Pax6 in the FlpIn-3T3 cell lines, Dkk3 was
downregulated in Pax6
Sey2/2 cortex compared to wild type mice
at day E15 in a published gene expression microarray [34].
Interestingly, with regard to Pax6 role in regulation of the Wnt
signaling pathway, Pax6 has recently been shown to be required
for downregulation of canonical Wnt signaling in the lens
ectoderm by directly controling the expression of the Wnt
inhibitors Sfrp1, Sfrp2 and Dkk1 [52].
A Pax binding site in the neural cell adhesion molecule (Ncam1)
promoter was identified as far back as in 1994 [53], and Pax6
binding to this site was subsequently shown [37]. Recently,
functional assays in Xenopus confirmed that Pax6 directly regulates
Ncam expression in retina [38]. These studies all identify Pax6 as
the regulator of Ncam expression. Importantly, in our study Ncam
was only detected as a target gene in the Pax6(5a) microarray, and
this was verified by real time PCR. However, we were not able to
detect binding to the Ncam1 promoter with two different primer
sets used in ChIP experiments (data not shown). If Pax6(5a) also
turns out to be the major activator of Ncam expression in vivo in
the brain and eye, then one would expect the different expression
ratios and expression patterns of Pax6 and Pax6(5a) to have
different effects on the Ncam expression.
The neuronal guanine nucleotide exchange factor (Ngef)i s
expressed in certain areas of the brain [54]. Ngef (also called
ephexin) interacts with EphA4 and constitutes a molecular link
between Eph receptors and the cytoskeleton. This upregulates the
activity of RhoA and downregulates Cdc42/Rac1 activity, as well
as induces changes in cell morphology [55]. EphA4 signaling is
also important for retinal axon guidance [56]. In our study Ngef
appears to be a target gene of Pax6(5a) only, being upregulated
about 12 fold compared to the control cell line. By ChIP we were
also able to detect direct binding of Pax6(5a) to the Ngef promoter
in the 3T3-Pax6(5a) cell line. Interestingly, we identified EphB2
and EphB4 as Pax6 specific target genes, with EphB2 being 2-fold
downregulated.by Pax6 and not affected by Pax6(5a) according to
qPCR results. EphB2 is reported to be involved in differential
growth cone collapse and axon retraction in retinal ganglion cells
[57].
Sphingosine kinase 1 (Sphk1) is a lipid kinase, catalyzing the
phosphorylation of sphingosine to sphingosine-1-phosphate. It is
one of the genes specifically downregulated by Pax6(5a) (about 3
fold as confirmed by qPCR), but seemingly not affected by Pax6.
Sphk1 is associated with oncogenesis. In addition to promoting
cellular survival, proliferation and transformation, it prevents
apoptosis and stimulates angiogenesis (reviewed in [58]). It is also
upregulated in several types of cancer one of them being
glioblastoma, where an elevated level of Sphk1 is associated with
poor prognosis [59]. Expression of Pax6 in glioblastoma multi-
forme (GMB) is associated with good prognosis [60], but in
published papers on PAX6 and glioblastoma the authors do not
distinguish between the two Pax6 isoforms. It is therefore not
known whether Pax6(5a) is expressed in glioblastoma, and in what
frequency compared to Pax6. This would be interesting to study
further with regard to the level of Sphk1, since not much is known
about the regulation of Sphk1 on the transcriptional level. Even
though qPCR confirmed the gene expression microarray results,
bioinformatic analysis could not detect any 5aCON half-sites in
the Sphk1 promoter tested. But since Sphk1 is registered with 17
transcripts having more than 10 different 59 starting points
(Ensembl genome browser), it is possible that we did not analyse
the correct Sphk1 promoter region.
Common target genes
Neuroblastoma, suppression of tumorigenecity, (Nbl1, also
named Dan or NO3) is a member of a class of secreted
glycoproteins which act as inhibitors of the transforming growth
factor beta and bone morphogenic protein pathway. It also acts as
a tumor suppressor, indicated by the fact that human Nbl1 is
mapped to a region of chromosome 1p often deleted in
neuroblastomas [61]. Further, overexpression of Nbl1 in trans-
formed fibroblast cell lines suppressed the transformed phenotype
and reduced growth rate [62]. In line with this, Nbl1 is found to be
overexpressed in pancreatic carcinoma [63]. Normal expression
pattern of Nbl1 during embryo development includes the eye, the
ear, floor plate of brain, somites and limb buds [64] as well as
specific areas in the brain [65]. Even though the microarray result
indicated Nbl1 to be a Pax6(5a) specific target gene, qPCR showed
that Nbl1 transcripts were repressed about 5–6 fold by both Pax6
and Pax6(5a). Inhibition of Nbl1 in vivo by Pax6/Pax6(5a) would
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active. Both the BMP and TGF beta signaling pathways are shown
to be active in and important for some of the tissues where Pax6 is
expressed during development (eye and brain) [66,67].
Connective tissue growth factor (Ctgf) encodes a cystein-rich
extracellular matrix associated protein, and was one of the genes
confirmed by qPCR to be upregulated by both Pax6 (6.8 fold) and
Pax6(5a) (3.8 fold). Ctgf is expressed in a number of different cell
types, but seems to be particularly important for normal
development of the skeleton since Ctgf null mice showed significant
skeletal defects [68]. Ctgf is a major contributor of fibrotic diseases
[69]. These properties do not immediately seem to be connected
to Pax6. However, Pax6 is involved in corneal wound healing
[70,71], and, interestingly, Ctgf is also shown to play a role in this
process, where it enhances attachment and migration [72].
Expression of Ctgf is reported to be influenced by cell shape
altering stimuli (reviewed in [73]). By the use of ChIP we showed
direct binding of Pax6 and Pax6(5a) to the Ctgf promoter.
Glycosyl transferases
We have verified that seven glycosyl transferases are downreg-
ulated by Pax6 and Pax6(5a) in the 3T3 cells. It is believed that
50% of all proteins are glycosylated, especially proteins expressed
on the cell surface or in the extracellular region. Changes in
glycosylation pattern are often observed in various diseases and in
cancer (reviewed in [74]). Some of the glycosyl transferases
identified in our study (Fut8, Mgat3, St6gal1) modify core
glycosylation structures on receptors and extracellular matrix
molecules [75,76]. In general, glycosylation is shown to play a role
in intra- and intercellular trafficking, molecular and cellular matrix
interactions, initiation of signal transduction and in the regulation
of processes such as cell growth, migration, differentiation and
tumor invasion [74,76] Interestingly, Gcnt2 is associated with
cataracts – a well known feature of mutant Pax6 phenotype [77].
Already in 1974 it was suggested that the mutant gene in small-eye
mice could be involved in synthesis or processing of glycoproteins,
since multiple glycoconjugate abnormalities were identified in
mutant eyes [78]. Kucerova and colleagues have now shown that
there are indeed alterations in the glycoconjugate signature of the
Pax6 mutant cells, and that these alterations restrict the ability of
the corneal epithelial cells to initiate migration in response to
wounding [79].
To conclude, we have generated FlpIn-3T3 cell lines expressing
only the Pax6 or Pax6(5a) isoform and this approach enabled us to
identify target genes specific for each of them. It also showed that
several genes are regulated by both of the two Pax6 isoforms
independently. These are important observations since in most
cells the two Pax6 isoforms are expressed together in specific
stochiometric relationships that may change over time during
development of some tissues. Future studies will be needed to show
if they synergistically activate the common target gene promoters.
Identification of already known Pax6 target genes and observation
of a link between identified target genes and known Pax6
associated biological processes indicate that the target genes found
in these 3T3 cell lines are highly relevant and can contribute to the
understanding of Pax6 and Pax6(5a) roles in normal development
and cancer.
Materials and Methods
Construction and maintenance of the FlpIn-3T3 Pax6 and
Pax6(5a) cell lines
FlpIn-3T3 cell lines (Invitrogen, R761-07) were grown in
DMEM high glucose supplemented with penicilin, streptomycin
and 10% fetal calf serum. Zeozin (100 mg/ml) was added for the
FlpIn-3T3 cells, while the FlpIn-3T3 cells constructed to express
Pax6 or Pax6/5a) were grown with hygromycin (150 mg/ml). Full
length mouse cDNA clones of mPax6 and mPax6(5a) in the
pENRTR1A vector were used as a starting point to clone mPax6
and mPax6(5a) into the pEF5/FRT/V5-DEST expression vector
with the Gateway Technology (Invitrogen). Lipofectamine and
Plus reagent (Invitrogen) were used for transfecting the Flp-In 3T3
cells according to the manufacturers recommendations. A ratio of
9:1 between pOG44 (Invitrogen) and the Pax6 or Pax6(5a)
expression plasmid was used in the co-transfection. Transfections
were done in 10 cm dishes, and transfection media (without
antibiotics and serum) was replaced with media with penicillin,
streptomycin and 10% fetal calf serum after 3 hours. Media
containing hygromycin (150 mg/ml) was added after 20 hrs to
select for stable transfectants. After 3–4 passages expression of
Pax6 and Pax6(5a) was confirmed by both RT-PCR and Western
blot.
Gene expression microarray
RNA was extracted from cells by use of Trizol according to the
manufacturer’s instruction (Invitrogen). Three individual RNA
preparations from two different cell passage numbers were used
for the FlpIn-3T3 control cell line and for the FlpIn-3T3 Pax6(5a)
cell line, while RNA from two different passage numbers were
prepared from the FlpIn-3T3 Pax6 cell line. The RNA was
shipped to the Turku Centre for Biotechnology (University of
Turku, Finland) where the sample quality was validated before the
samples were processed and used in microarray on a Illumina
Mouse Ref-8 V1.1 chip (project 070078). In total 24613 transcripts
were on the chip. The data was normalized using the Quantile
normalization method, and the R package Limma was used for
performing the comparisons between the groups (done by the
Turku Centre for Biotechnology). Two sets of thresholds were
used for filtering. List of genes obtained by threshold 1 had a false
discovery rate (FDR) p-value of 0.001, a cut off for fold change
(FC) at 1.7 and the logFC at 0.77. For threshold 2, (FDR) p-value
was set to 0.01, FC 1.5 and logFC 0.58. The data have been
submitted to the GEO repository (accession number GSE31402).
Western Blot
Cell lysates were incubated with sample buffer for 5 minutes at
100uC and run on a 10% SDS-PAGE gel (Mighty Small,
Invitrogen). Blotting was performed onto a Hybond nitrocellulose
membrane (GE Healthcare) using the Mighty Small blotting
system (Invitrogen). The membrane was incubated with blocking
buffer (PBS buffer/0.1% Tween-20/5% non-fat dried milk).
Primary and secondary antibodies were diluted in the blocking
buffer. Rabbit anti-Pax6 antibody (Millipore, cat#AB2237) was
used in the dilution of 1:1200, and rabbit anti-actin (Sigma,
cat#A2066) 1:2000. Anti-rabbit HRP-conjugate (BD Pharmin-
gen, cat#554021) 1:2000, and anti-biotin HRP-linked antibody
(Cell Signaling, cat#7075) 1:2000. Molecular weight markers used
were Prestained Protein marker, Broad range (NEB, cat#77077S)
and Biotinylated protein marker (Cell Signalling, cat#7727).
Western blots were developed with the Western Blotting Luminol
Reagent (Santa Cruz, cat#sc-2048) and images were acquired on
an Image Reader LAS-3000 Fujifilm.
RNA extraction and RT-PCR
Total RNA was extracted from cell cultures with use of the
Trizol reagent according to the manufacturer’s instructions
(Invitrogen). Genomic DNA was removed by DNAse treatment
according to the RNeasy Micro Kit protocol (Qiagen). Tran-
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cDNA with use of random Hexamer primers supplied by
Pharmacia. 5 mg RNA was used as input in a 40 ml reaction.
2 ml cDNA was used as input in a RT-PCR reaction with primers
directed against HPRT. Volume of cDNA input was adjusted
before gene specific primers were used (Pax6, Gcnt1, Gcnt2,
St3gal6, St6gal1, Fut8, Mgat3, Ugt1a7c), see Table S3. PCR was
performed using DyNAzyme (Finnzymes), annealing temperature
of 57uC/30 cycles. PCR products were run on 1% agarose gels
and visualized by the use of ethidium bromide. The procedure was
repeated 3 times for each primer set.
RNA extraction and reverse transcription quantitative
PCR (RT-qPCR)
Total RNA was purified using the RNeasy Plus kit from Qiagen
(Hilden, Germany) according to the manufacturer’s instructions.
Quantity and purity of the extracted RNA was then determined
with the NanoDrop spectrophotometer (Thermo Fisher Scientific,
Wilmington, DE). Reverse transcription of total RNA was
performed using Superscript III Reverse Transcriptase kit
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
recommendations using 150 ng random hexamer primers (Fer-
mentas International Inc., Canada). dNTP mix was purchased
from Promega (Madison, WI). 500 ng total RNA was used per
20 ml cDNA reaction.
For quantification of mRNA expression levels, a Stratagene
MX3000P instrument (Stratagene, La Jolla, CA) was used. Primer
pairs were designed using Primer 3 software (Whitehead Institute,
Cambrigde, MA) [80] and synthesized by Invitrogen (Table S4).
Primers for one of the housekeeping genes (mTfrc) were purchased
directly from Qiagen (Quantitect primer assay, QT00122745). So
were primers for mTgfbi (Quantitect primer assay, QT00105770).
cDNA corresponding to 25 ng RNA was amplified for 40 cycles
in a 25 ml SYBR green PCR mix (Brilliant II SYBR Green QPCR
master mix, Stratagene) containing 200 nM of each primer.
Cycling conditions were 95uC for 10 min followed by 40 cycles at
95uC for 30 sec, 60uC for 1 min and 72uC for 30 sec. A SYBR
green melting curve analysis was included to determine primer
specificities and confirm the absence of primer dimers.
Duplicate PCR analyses were performed on each cDNA
sample. The absence of genomic DNA and contaminations were
confirmed by the inclusion of no reverse transcriptase (No RT)
controls and no template controls (NTCs) respectively. The
relative amount of target gene normalized to the average
expression of the two reference genes Tfrc and Nono was
determined using the DDCq-method [81].
ChIP
Cells of 70–80% confluence were crosslinked in freshly prepared
1% formaldehyde for 7 minutes at room temperature. The
crosslinking was stopped by adding 0.125 M glycine. Cells were
harvested in lysis buffer containing 1% SDS, 50 mM Tris
(pH 8,0), 10 mM EDTA and protease inhibitor cocktail
(cat#11836153001, Roche, Germany). Chromatin was sonicated
for 20 minutes using Bioruptor UCD-200 (Diagenode, Belgium),
and diluted 106 with a buffer containing 0,01% SDS, 1,1%
Triton X-100, 1,2 mM EDTA, 16,7 mM Tris (pH 8,0), 167 mM
NaCl and protease inhibitor cocktail. For immunoprecipitation we
used 1.0 mg of either of the following antibodies: human IgG
(Abcam, UK, cat#AB46540-1) or anti-Pax6 (Millipore, USA,
cat#AB2237). Protein A-agarose beads were purchased from
Santa Cruz, USA (cat#sc-2001), pre-blocked with a mixture of
1% BSA and sonicated salmon sperm DNA (Agilent Technologies,
USA, cat#201190). After IP beads were washed 4 times. Reversal
of cross-links and elution of PCR-ready DNA were identically
performed on immunoprecipitated DNA-protein complexes and
input chromatin samples essentially as described (Nelson 2006).
Chelex-100 beads were purchased from BioRad, USA (cat#142-
1253) and proteinase K from Invitrogen, USA (cat#25530-015).
For PCR-based verification of in vivo binding, we used a ready-
made DyNAzyme II PCR Master Mix (Finnzymes/Thermo
Fisher, USA, cat#F508). Each PCR reaction had a total volume
of 25 ml with 2,0 ml template. Sequences of primers designed by
Primer3 software are shown in Table S4.
Proliferation assay
3T3 cells (control, Pax6, Pax6(5a)) were trypsinised briefly until
detached. Cells were resuspended in complete growth media and
counted. Optimal cell number per well (5000) was determined in
initial titration experiments. According to xCELLigence (Roche)
manufacturer’s instructions, cells were seeded in duplicates into E-
plates 16 (Roche, cat# 05469830001) after baseline measurement.
Plates were incubated for 1 hour at room temperature, and
then placed into the RTCA DP instrument (Roche, cat#
05469759001) located in an incubator preserving same temper-
ature and CO2 concentration as were used for routine cultivation
of 3T3 cells. Cell index (arbitrary unit reflecting the cell-sensor
impedance) was measured every 15 minutes during the first
4 hours for better resolution at attachment and spreading phase.
Further measurements were taken every 30 minutes. Slope and
doubling time calculations were performed with RTCA software
1.2 (Roche). Four independent experiments were performed.
Migration assay
Cells were serum-starved for 24 hours, trypsinised briefly until
detached, then immediately resuspended in serum-free growth
media. After centrifugation media was removed, pellets resus-
pended in serum-free media and cell numbers counted. Optimal
cell number per well (20000) was determined in an initial titration
experiment. According to xCELLigence manufacturer’s instruc-
tions, cells were seeded in duplicates into uncoated CIM-plates 16
(Roche, cat# 05665817001) after baseline measurement. Media
below membrane contained 10% of freshly thawn fetal calf serum.
Plates were incubated for 1 hour at room temperature before
starting the routine measurements. Cell index was measured every
15 minutes during 24 hours (duration of the experiment was
limited based on manufacturer’s advice to prevent errors caused
by proliferation of the cells on the outer side of the membrane).
Slopes were calculated with RTCA software 1.2. Three indepen-
dent experiments were performed.
Bioinformatic analyses
For Gene ontology analyses the Database for Annotation,
Visualisation and Integrated Discovery (DAVID) [40,41] was
used. We used the lists of up- or downregulated genes (threshold 1)
as inputs. A list of all genes on the Illumina Mouse Ref-8 V1.1 chip
was provided as reference (background). The eGOn database
(http://www.genetools.microarray.ntnu.no/adb/index.php) [42]
was used to compare the list (both threshold 1 and threshold 2)
of upregulated genes with the list of downregulated genes.
For Pax6 binding site analyses ConSite [82] was used to look for
Pax6 and Bsap (Pax5) binding sites. The Bsap bs was included
because Pax5 and Pax6 have similar DNA binding preferences [6].
ConSite does not have the Pax6(5a) bs as an option. To look for
Pax6(5a) binding sites in selected target gene promoters, the
5aCON halfsite (ATGYTCAKTGA) [9] was used in the Genetics
Computer Group (GCG) package with the findpatterns option, with
allowed mismatch set to 2. Similar GCG analyses were also done
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[16] and the Pax6 consensus site (RNGMANTSAWGCGTRAA)
[6] The input to the ConSite and GCG analyses were promoters
of selected target genes, identified by use of the Ensembl genome
browser by including 2000 bp upstream and 500 bp downstream
of the transcriptional start site (TSS) in exon 1 of the gene of
interest. The identities of the transcript (and thus the regulatory
regions) used for these analyses are given in table 6 and Table S3.
For extended promoter analyses and comparison of evolution-
ary conserved sites, promoter areas 5000 bp upstream and
1000 bp downstream of the TSS of exon 1 (Ensembl) of selected
target genes were used. The region corresponding to the promoter
of the orthologous human gene/transcript was included. Some of
the genes chosen for analyses had several transcripts and several
different first exons. The NCBI browser (align 2 sequences option)
was used to align the mouse and human sequences so that the
correct/comparable promoters were used for downstream analy-
ses. If found, the orthologous chicken and zebrafish promoters
were also included. Location of these promoter regions in the
genome is specified in table 6. The promoter sequences were
analysed by use of rVISTA [83] for evolutionary conserved Pax6
binding sites.
Supporting Information
Table S1 Pax6 regulated genes (threshold 1).
(XLS)
Table S2 Pax6(5a) regulated genes (threshold 1).
(XLS)
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